Verana Health Receives New Product Innovation Award from Frost & Sullivan for Its VeraQ Population Health Data Engine

Verana Health’s VeraQⓇ population health data engine transforms structured and unstructured EHR data into curated, quality data (Qdata®) to power insights on care quality, treatment patterns and outcomes, clinical trial site selection, therapeutic market share, and more. The engine ingests and curates de-identified EHR data from three unparalleled databases: the American Academy of Ophthalmology IRISⓇ Registry (Intelligent Research in Sight), the American Urological Association Quality Registry (AQUA), and the American Academy of Neurology Axon Registry. It then often links the de-identified data to other sources such as medical and pharmacy claims, diagnostic images, genomics, and mortality data. Verana Health maintains, protects, and curates its data ecosystem using clinician oversight, natural language processing, and machine learning. It also provides insights closer to real time into the overall drug lifecycle. The platform leverages information on:

• More than 500 million patient visits
• More than 20,000 contributing clinicians
• More than 9 years of longitudinal data
• Approximately 90 million de-identified patients
• More than 70 contributing EHR systems
• 3 therapeutic areas

Unmesh Lal, a Frost & Sullivan research director specializing in healthcare, observed, “Information technology solution providers explore value creation and extraction from the growing RWD volumes to enhance patient recruitment and engagement, reduce trial costs, and increase longitudinal trials and digital patient data.”

VeraQ creates curated, fit-for-purpose data modules, called Qdata, to help answer complex questions requiring observational inputs from de-identified clinician notes and EHR records. VeraQ is the foundation for quality insights derived from RWD across clinical research. Qdata in ophthalmology, urology, and neurology help to power observational research studies and accelerate trial activity, identifying patients cohorts that may qualify for select clinical trials.

“Verana Health developed a lifecycle solution model for life sciences ranging from clinical development to market expansion. Ultimately, it integrates a customer-centric approach to ensure its offering addresses users’ wants and needs,” added Manuel Albornoz, a Frost & Sullivan Best Practices Research analyst. For its strong overall performance, Verana Health is recognized with Frost & Sullivan’s 2022 North America New Product Innovation Leadership in the RWE solutions industry.

Each year, Frost & Sullivan presents this award to the company that develops an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.